Summary: In addition to the recognized and documented therapy with bronchodilators (long-acting beta2-agonists and long-acting anticholinergic drugs), the latest guidelines of the GOLD Report have reserved a special position for the combination of the above-mentioned medications with inhaled glucocorticoids. Considering the fact that the GOLD guidelines in subsequent editions place more and more emphasis on better stratification of patients to clinical groups and more individualized treatment, ICS + LABA combination therapy has found its specific, important position in selected, well-classified groups of patients, i.e. group C (selected clinical situations) and group D (selected clinical situations). For patients in category C, if there are further exacerbations, LAMA + LABA is preferred, but the alternative for this combination is ICS + LABA. Also, ICS + LABA therapy can be the first-choice treatment in the D category of patients in selected clinical situations, i.e. in the case of asthma/COPD overlap syndrome and/or the coexistence of peripheral blood eosinophilia.